Nature Reviews Rheumatology

Article	Citations
Inflammatory arthritis affects men’s fertility	542
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	409
Bimekizumab effective across the axSpA spectrum	355
No benefit from adding MTX to ustekinumab	328
Targeting articular Mmp13 in OA	288
Low-dose rituximab can go even lower	269
Genome-wide mutagenesis reported in systemic sclerosis	258
Rheumatic diseases on the rise	238
A role for TGFβ and EBV in MIS-C pathogenesis	216
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	209
New drug formulation reduces bone loss	177
Biological and clinical roles of IL-18 in inflammatory diseases	177
FOXP3 splice variant is associated with autoimmune disease	175
Towards better management of sterile bone inflammation	165
Use of platelet-rich plasma for knee OA not supported by RCT results	163
MIS-C: myths have been debunked, but mysteries remain	149
Ageing stem cells hold the key to age-related bone degeneration	147
Urchin-like nanoparticles for miRNA therapy of OA	144
2021 ACR guideline for JIA reflects changes in practice	136
The 2022 ACR vaccination guideline: a call-to-action	132
The value of comparative efficacy studies in informing rheumatology guidelines	126
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	117
To choose or not? The value of discrete-choice experiments in rheumatology	109
Appraising the evolving landscape of protease inhibition in osteoarthritis	107
Down syndrome: insights into autoimmune mechanisms	104

Inflammation across tissues: can shared cell biology help design smarter trials?	104
Which NSAIDs are best for OA treatment?	101
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	99
Co-trimoxazole reduces mortality in anti-MDA5-DM	98
Low-dose glucocorticoids benefit seniors with RA	97
S100A4 inhibition targets fibrosis in SSc	95
Calprotectin tracks tocilizumab-treated RA	92
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	85
Wnt-induced IGF1 drives OA	85
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	85
Author Correction: Proposals for the rheumatological use of JAK inhibitors	84
Guiding ILD management in systemic autoimmune rheumatic diseases	83
A direct link between SARS-CoV-2 and bone loss	82
Rheumatology in the digital health era: status quo and quo vadis?	80
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	78
Rheumatic diseases and metabolism: where centre and periphery meet	77
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	76
Low back pain is a growing concern	76
sCD13 role in arthritis mediated via bradykinin receptor	75
Fumarate drives interferon release in systemic sclerosis monocytes	75
Antibiotics keep rheumatic heart disease at bay	72
Targeting the IVD clock to halt degeneration	71
Erosive cargo from synovial fibroblasts	70
Which DMARD for ICI-associated arthritis?	69
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	67
Macrophage-coated nanocarriers for gouty arthritis	65
ERAP1 and the return of the UPR in ankylosing spondylitis	65
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	64
Insights into IVDD pathogenesis in 2024	63
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	62
A path towards personalized medicine for autoinflammatory and related diseases	62
PGE2 receptor antagonist has potential to treat osteoarthritis	62
CAR T cells induce drug-free SLE remission	61
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	60
Antibodies induce fibromyalgia symptoms	58
Blocking CDK7 attenuates inflammatory arthritis	56
RA risk from occupational inhalation	55
PPIs linked to increased risk of knee replacement	55
Mysteries of kidney-protecting parasitic infection revealed	55
TASL has a key role in SLE	55
Two sides of management recommendations for psoriatic arthritis	54
Improving the design of RCTs in non-radiographic axial spondyloarthritis	54
All fibroblasts are equal, but some are more equal than others	53
Is air pollution linked with poor response to biologics?	51
Repolarizing macrophages using antagomirs	51
A leading role for interferon as a treatment target in Sjögren syndrome	50
New hope for B cell-targeting therapy in pSS	50
New refinements aim to optimize articular cartilage tissue engineering	48
A critical view of WHO guidelines on management of low back pain	47
Profiling joint tissues at single-cell resolution: advances and insights	45

New developments in electronic health record analysis	45
CXCL5 effective in mouse model of SLE	44
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	44
Treg cell-inducing nanoparticles show promise for treating OA	44
Piezo1 induces new bone formation in AS	43
Author Correction: Glycobiology of rheumatic diseases	42
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	41
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	39
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	39
APOE in fat pad and synovium contributes to knee OA	38
AhR promotes suppressor cell function in Sjögren syndrome	38
Sex- and gender-based personalized medicine in rheumatology	36
Pathogenic antibodies target stromal antigens in RA	35
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	35
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases	34
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	34
Critical appraisal of serum urate targets in the management of gout	33
Are DNA–HLA class II interactions the missing link in SLE?	33
Imaging for prediction of RA development	33
Stromal cells implicated in RA genetic risk	33
B cell X-chromosome inactivation is faulty in SLE	32
New OA risk factors and drug targets revealed	32
HLA autoimmunity risk alleles influence T cell receptor sequences	32
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	31
Shifting the SLE management paradigm: challenges and implications	31
BiTE therapy for rheumatic diseases	29
FABP4 exacerbates RA	28
Post-transcriptional checkpoints in autoimmunity	27
Mechanisms and clinical implications of intervertebral disc calcification	26
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	26
COVID-19 linked to rise in anti-MDA5 autoimmunity	24
Guselkumab effective through 2 years in PsA trial	24
Detachment promotes RA synovial fibroblast survival and invasiveness	23
PLG nanoparticles target inflammatory monocytes in SSc	23
Multi-omics reveals distinct MPA subtypes	22
Adropin inhibits fibrosis in SSc	21
Notch signalling mediates OA pain in mice	21
Complement therapeutics are coming of age in rheumatology	20
Tildrakizumab shows promise in phase IIb study	19
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	19
State-of-the-art evidence in the treatment of systemic sclerosis	19
The potential contribution of in silico studies to improved treatment of osteoarthritis	19
Busting the myth of methotrexate chronic hepatotoxicity	19
Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer	18
Treatment of non-systemic juvenile idiopathic arthritis	18
Citrulline immunity in RA: CD8+ T cells enter the scene	18
How the COVID-19 pandemic has affected rheumatology research	18
Targeting calcium-related mechanotransduction in early OA	17
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells	17
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	16
Primary care rheumatology: towards sustainable development in health	15
Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms	15
Update on the pathophysiology and treatment of primary Sjögren syndrome	15
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	14
Shedding light onto the immunometabolic effects of glucocorticoids	14
The immune health metric as an indicator of health and disease	14
UNC93B1 variants promote SLE via TLR activation	13
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	13
Genome editing to define the function of risk loci and variants in rheumatic disease	13
Bone-modifying drugs slow OA progression	13
Undiagnosed axSpA is prevalent in IBD	13
The PU.1– IL-9 axis in TH9 cells promotes RA	13
Combination therapy for Behçet uveitis	13
No benefit to intensive urate lowering in gout	13
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	13
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	13
Glycosylation switch in synovial fibroblasts promotes ECM degradation	12
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	12
Interleukin-2 and regulatory T cells in rheumatic diseases	12
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies	11
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	11
Reversal of inflammatory priming prevents arthritic flares	11
Advances in the calculation of minimal important change estimates for patient-reported outcome measures	11
T cell differentiation in Sjögren syndrome is regulated by TOX	11
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications	11
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	11
Paediatric glucocorticoid toxicity index: new possibilities in assessment	11
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	11
Combining TNF blockade with immune checkpoint inhibitors in patients with cancer	10
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	10

Novel TLR7 variant causes lupus	10
Disease stratification in GCA and PMR: state of the art and future perspectives	10
Evidence-Based Guideline for the management of osteoporosis in men	10
Real-world data provide insights into PsA treatment patterns	9
PPM1A: TGFβ regulator and therapeutic target in OA	9
MIS-C: how do patients fare 6 months on?	9
Pregnancy outcomes improving in axSpA	9
CD38hiCD8+ T cells characterize ICI-mediated arthritis	9
Treat-to-target or treat-to-dissolve strategy to improve gout treatment	8
Macrophages hit a nerve in painful joint venture	8
When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy	8
GCA management guidelines — vive la différence?	7
Benralizumab noninferior to mepolizumab for EGPA	7
Kindlin-2 reduces IVD inflammation	7
Author Correction: New genes, pathways and therapeutic targets in autoinflammatory diseases	7
Annexin A1 could help prevent periprosthetic bone loss	7
Imaging in inflammatory arthritis: progress towards precision medicine	7
A new immunometabolic perspective of intervertebral disc degeneration	7
PJP prophylaxis with rituximab	7
Gut T cells help mediate fracture healing	7
Age-related mechanisms in the context of rheumatic disease	7
New treatments for amyloidosis	6
Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis	6
High risk of autoimmune diseases after COVID-19	6
TGFβ priming promotes TNF-induced bone erosion: a promising new target in RA?	6
New guideline for integrative approaches to RA management	6
ZEB2 promotes formation of age-related B cells	6
Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity	6
Knee OA progression risk with steroids or HA	6
Optimizing methotrexate withdrawal during COVID vaccination	6
Lupus nephritis-related chronic kidney disease	6
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout	6
Lyme arthritis: linking infection, inflammation and autoimmunity	5
Does psoriasis treatment affect PsA development?	5
ETS1 implicated in polarization of tissue-destructive fibroblasts	5
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone	5
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration	5
New screening tool developed to aid diagnosis of axial PsA	5
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity	5
Relapsing polychondritis: clinical updates and new differential diagnoses	5
Pregnancy outcomes in SLE have not improved	5
IRAK4 inhibitor attenuates inflammation	4
Mechanism of B cell survival in lupus nephritis	4
Limitations of the updated EULAR recommendations for osteoarthritis	4
SLE risk variant regulates IRF8 expression	4
Collagen-binding antibody prevents arthritis	4
Integrin signalling in joint development, homeostasis and osteoarthritis	4
Integrin-mediated ILC2 adhesion protects against lupus nephritis	4
Sarcoidosis: can tofacitinib slay the dragon?	4
How muscle influences bone health	4
The peculiar features, diversity and impact of citrulline-reactive autoantibodies	4
The role of mitochondria in rheumatic diseases	4
Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress	4
Targeting UHRF1 in RA	4
JAK inhibitors improve RA pain	4
Reply to: Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups	4
Understanding synovial cell diversity in post-traumatic OA	4
Cardio-rheumatology: it’s time to collaborate	4
VEXAS syndrome more common than originally thought?	4
Reply to: TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out	3
Joint location matters for TNF inhibitor treatment in PsA	3
Challenges in the management of older patients with inflammatory rheumatic diseases	3
Treating inflammatory arthritis in individuals with concomitant cancer	3
Modifying exosomes to target macrophages in arthritis	3
Is X chromosome inactivation a cause or effect of SLE?	3
Fibroblasts in immune responses, inflammatory diseases and therapeutic implications	3
T cells in Sjögren disease	3
New evidence for the ‘cusp theory’ to explain HLA associations in SLE	3
Reply to: Hypothetical model ignores many important pathophysiologic mechanisms in fibromyalgia	3
Understanding rheumatic disease through continuous cell state analysis	3
Hypoxia-modifying hydrogel supports stem cells for joint repair	3
A roadmap for delivering a human musculoskeletal cell atlas	3
Breaking research silos to achieve equitable precision medicine in rheumatology	3
A comprehensive guide for managing the reproductive health of patients with vasculitis	3
Pentose phosphate pathway metabolite restores T cell balance in SLE	3
PR3 triggers granuloma formation in GPA	3
Publisher Correction: IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	3
The therapeutic potential of immunoengineering for systemic autoimmunity	3
Metabolic reinvigoration of immune tolerance	3
Intervertebral disc degeneration and osteoarthritis: a common molecular disease spectrum	3
Sex and gender matter for TNF inhibitor therapy in RA	3
NK cells induce a pro-inflammatory phenotype in RA synovial fibroblasts	3
A subset of ITGA5+ synovial fibroblasts alter the inflammatory niche in RA	3
Targeting IL-23 for axial disease in PsA	3
Joint-on-chip platforms: entering a new era of in vitro models for arthritis	3
Nasal chondrocytes enable cartilage repair in OA joints	3
A basket genetic trial of the vasculitides	3
CXCL7 promotes bone erosion in RA	2
Restoring cartilage lubrication to heal post-traumatic OA	2
Advancements and challenges in CAR T cell therapy in autoimmune diseases	2
Promise and challenge of systemic sclerosis therapies	2
How does citrullination contribute to RA autoantibody development?	2
Treatment of lupus nephritis: consensus, evidence and perspectives	2
Rethinking antiphospholipid syndrome to guide future management and research	2
A safe and effective treatment for MAS	2